Currently, for HNSCC, 4 clinical trials currently evaluate the efficacy of Ad-p53 either alone or in combination with other treatments such as immune checkpoint inhibitors or the standard of care, concomitant chemoradiotherapy (NCT02842125, NCT00003257, NCT00017173, NCT03544723). Here, TP53 is linked to head and neck squamous cell carcinoma.